NASDAQ:AGIO
Agios Pharmaceuticals Stock News
$29.03
+0.230 (+0.799%)
At Close: Apr 17, 2024
Delta Air Lines, Fastenal And 3 Stocks To Watch Heading Into Wednesday
07:38am, Wednesday, 13'th Jul 2022 Benzinga
With the US stock futures trading slightly higher this morning on Wednesday after recording losses in the previous session, some of the stocks that may grab investor focus today are as follows:
Wall
Agios Appoints Brian Goff as Chief Executive Officer
08:01pm, Tuesday, 12'th Jul 2022 GlobeNewswire Inc.
– Current CEO, Jackie Fouse, Ph.D., to Transition to Chair of Board of Directors Effective August 8, 2022 –
Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress
02:30pm, Friday, 10'th Jun 2022 GlobeNewswire Inc.
– Treatment with PYRUKYND® Associated with Early and Robust Hemoglobin Responses in Phase 3 ACTIVATE and Extension Studies; Approximately One-Third of Patients Achieved Normal Hemoglobin Levels at
7 Analysts Have This to Say About Agios Pharmaceuticals
01:12pm, Tuesday, 17'th May 2022 Benzinga
Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
1
2
0
1
Agios Announces Evolution of Research Organization
08:15pm, Monday, 16'th May 2022 GlobeNewswire Inc.
– Sarah Gheuens, M.D., Ph.D., to be Named Head of R&D, Chief Medical Officer; Chief Scientific Officer Bruce Car to Step Down at the End of July –
Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress
10:00am, Thursday, 12'th May 2022
– Agios to Present New Patient-Reported Outcomes (PRO) Data from ACTIVATE Phase 3 Study of PYRUKYND ® (mitapivat) in Adults with PK Deficiency Who Do Not Receive Regular Transfusions –
Agios: Approved Product, Upcoming Catalysts
01:22pm, Tuesday, 10'th May 2022
Mitapivat got approved for PK deficiency. They have multiple label expansion potential.
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022
11:00am, Tuesday, 10'th May 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, tod
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022
07:00am, Tuesday, 10'th May 2022
CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
12:43pm, Thursday, 05'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
The�
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates
12:15pm, Thursday, 05'th May 2022 Zacks Investment Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.95% and 57.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q1 2022 Results - Earnings Call Transcript
11:24am, Thursday, 05'th May 2022
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Jackie Fouse – Chief Executive Officer Sarah Gheuens – Chief Medical Officer
Agios Reports Business Highlights and First Quarter 2022 Financial Results
11:00am, Thursday, 05'th May 2022 GlobeNewswire Inc.
– Received U.S. FDA Approval for PYRUKYND®, the First Therapy for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) deficiency and Agios’ First Genetically Defined Disease Med
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates
09:47am, Thursday, 05'th May 2022
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.95% and 57.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022
07:00am, Thursday, 21'st Apr 2022
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, tod